← Leaderboards
Diane M Simeone
University Of Michigan At Ann Arbor
$15,596,624
Attributed
$18,886,955
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,153,310 · 17
By mechanism
P30$12,223,604 · 4
R01$11,070,663 · 5
U01$1,767,817 · 1
P01$1,683,930 · 1
P50$952,104 · 1
T32$825,654 · 1
Top collaborators
- Agnel Sfeir5 shared
- Dafna Bar-Sagi3 shared
- Jessica Everett2 shared
- Deepak Saxena2 shared
- Aristotelis Tsirigos1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Ariel L Barkan$3,620,723
- Phillip L Palmbos$2,630,125
- Matthew J Dimagno$1,671,837
- David Thomas$1,373,464
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMediatingBaseMalignant Neoplasm Of PancreasNew Therapeutic TargetGenesSignal TransductionNeoplasm MetastasisMolecularPathway InteractionsIn VivoDiagnosisResponseOverexpressionPancreatic AdenocarcinomaTissuesGrowthMouse ModelDna DamageResistanceTumorPhenotypeLeadTumorigenesis
Grant awards (56)
Biomarker Validation in Pancreatic Cystic Neoplasms$49,500
U01 · FY2025 · CA · contact PI
Specialized Cancer Center Support Grant$5,025,039
P30 · FY2024 · CA · contact PI
Biomarker Validation in Pancreatic Cystic Neoplasms$820,061
U01 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$739,350
P30 · FY2024 · CA · contact PI
Developmental Funds$723,708
P30 · FY2024 · CA · contact PI
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma$523,841
R01 · FY2024 · CA · contact PI
Administrative Core$494,191
P30 · FY2024 · CA · contact PI
Specialized Cancer Center Support Grant$4,994,092
P30 · FY2023 · CA · contact PI
Biomarker Validation in Pancreatic Cystic Neoplasms$898,256
U01 · FY2023 · CA · contact PI
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma$656,180
R01 · FY2023 · CA · contact PI
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis$334,322
P01 · FY2023 · CA · contact PI
Specialized CCSG supplement SODH and Quality of Cancer Care in HIV-associated Cancers$247,224
P30 · FY2023 · CA · contact PI
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma$666,466
R01 · FY2022 · CA · contact PI
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis$328,468
P01 · FY2022 · CA · contact PI
Research Training for Physician-Scientists in Gastrointestinal Oncology$279,061
T32 · FY2022 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma$690,258
R01 · FY2021 · CA · contact PI
Regulation of Pancreatic Oncogenesis by the Gut Microbiome$375,150
R01 · FY2021 · CA · contact PI
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis$335,171
P01 · FY2021 · CA · contact PI
Research Training for Physician-Scientists in Gastrointestinal Oncology$262,726
T32 · FY2021 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma$700,147
R01 · FY2020 · CA · contact PI
Regulation of Pancreatic Oncogenesis by the Gut Microbiome$375,150
R01 · FY2020 · CA · contact PI
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis$342,771
P01 · FY2020 · CA · contact PI
Research Training for Physician-Scientists in Gastrointestinal Oncology$283,867
T32 · FY2020 · CA
Early Detection Biomarkers in Pancreatic Adenocarcinoma$390,486
R01 · FY2019 · CA · contact PI
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis$343,198
P01 · FY2019 · CA · contact PI
Oncogenic Function of ATDC in Bladder Cancer$485,833
R01 · FY2018 · CA · contact PI
Early Detection Biomarkers in Pancreatic Adenocarcinoma$402,563
R01 · FY2018 · CA · contact PI
Oncogenic Function of ATDC in Bladder Cancer$485,833
R01 · FY2017 · CA · contact PI
Early Detection Biomarkers in Pancreatic Adenocarcinoma$402,563
R01 · FY2017 · CA · contact PI
2017 Pancreatic Diseases Gordon Research Conference$20,000
R13 · FY2017 · DK · contact PI
Oncogenic Function of ATDC in Bladder Cancer$444,272
R01 · FY2016 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$368,125
R01 · FY2016 · CA · contact PI
Oncogenic Function of ATDC in Bladder Cancer$444,631
R01 · FY2015 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$368,422
R01 · FY2015 · CA · contact PI
2015 Pancreatic Diseases Gordon Research Conference$15,000
R13 · FY2015 · DK · contact PI
Oncogenic Function of ATDC in Bladder Cancer$445,705
R01 · FY2014 · CA · contact PI
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer$150,103
P50 · FY2014 · CA · contact PI
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer$256,832
P50 · FY2013 · CA · contact PI
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer$183,018
P50 · FY2012 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$308,573
R01 · FY2011 · CA · contact PI
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer$179,834
P50 · FY2011 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$318,188
R01 · FY2010 · CA · contact PI
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer$182,317
P50 · FY2010 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$318,258
R01 · FY2009 · CA · contact PI
ATDC Function in Human Pancreatic Adenocarcinoma$318,326
R01 · FY2008 · CA · contact PI
Studies of Pancreatic TGFBeta-Mediated Signaling$300,842
R01 · FY2007 · DK · contact PI
Studies of Pancreatic TGFBeta-Mediated Signaling$310,647
R01 · FY2006 · DK · contact PI
Studies of Pancreatic TGFBeta-Mediated Signaling$319,640
R01 · FY2005 · DK
Studies of Pancreatic TGFBeta-Mediated Signaling$319,792
R01 · FY2004 · DK
Surgical Study of Pancreatic TGFBeta-Mediated Signaling$330,772
R01 · FY2003 · DK
TGFB SIGNALING PATHWAY IN THE PANCREAS$114,885
K08 · FY2003 · DK
TGFBeta Signaling Mechanisms in the Pancreas$72,848
R03 · FY2003 · DK
TGFB SIGNALING PATHWAY IN THE PANCREAS$114,885
K08 · FY2002 · DK
TGFBeta Signaling Mechanisms in the Pancreas$72,950
R03 · FY2002 · DK
TGFB SIGNALING PATHWAY IN THE PANCREAS$109,485
K08 · FY2001 · DK
TGFB SIGNALING PATHWAY IN THE PANCREAS$109,485
K08 · FY2000 · DK